Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. IBM
9. HOOD
10. DFTX

Go back to Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
(NASDAQ: IOVA) Delayed: 4.06 --0 (-0%)
Previous Close $4.06    52 Week High $ 
Open $4.06    52 Week Low $ 
Day High $4.06    P/E N/A 
Day Low $4.06    EPS $ 
Volume 61,673